

**APPENDIX G: Office Action of February 8, 2000**



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/674,311	07/01/96	OLOPADE	ARSB:509

BARBARA S KITCHELL  
ARNOLD WHITE & DURKEE  
PO BOX 4433  
HOUSTON TX 77210-4433

HM11/0208

EXAMINER

ARTHUR, L

ART UNIT	PAPER NUMBER
1655	23

DATE MAILED: 02/08/00

REC'D. - A. W. & D.

FEB 15 2000

HOUSTON DOCKETING DEPT.

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

FULBRIGHT & JAWORSKI LLP  
AUSTIN, TEXAS

FEB 17 2000

RECEIVED

DOCKETED  
DATE  
INITIALS

5/8/00 - Resp. to O.A.  
8/8/00 - Resp to OA - final deadline  
OAC

ARSB 509-1

DOCKETED	<input type="checkbox"/>	UPDATED	<input type="checkbox"/>
Previously	<input checked="" type="checkbox"/>	Not Required	<input type="checkbox"/>
Appl. Info			
Reg/Grant Info			
Action Required:	D-O-D		
Date Due/Done:	A		
By:	GJA		
Checked:	A		

BEST AVAILABLE COPY

# Office Action Summary

Application No.  
08/674,311

Applicant(s)

Olopade

Examiner  
Lisa Athur

Group Art Unit  
1655



☒ Responsive to communication(s) filed on Aug 19, 1999

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claim

☒ Claim(s) 39-96 is/are pending in the application

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 39-96 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

**REC'D. - A. W. & D.**

**FEB 15 2000**

**HOUSTON DOCKETING DEPT.**

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☒ None of the CERTIFIED copies of the priority documents have been received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

Art Unit: 1655

1. This application is a continuing prosecution application filed under 37 CFR 1.53(d).

Currently claims 39-96 are pending. This action contains new grounds of rejection.

**MAINTAINED REJECTIONS**

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 39-50,52-57,59,60, 67-76,78,80-83,88-94 are rejected under 35 U.S.C. 102(b) as being anticipated by Kamb et al. (1994).

Kamb et al. Teach isolated polynucleotides containing the tumor suppressor gene MTS1 which maps to 9p21-22. The cosmid that contains MTS1 of Kamb et al. Also contains the human methylthioadenosine phosphorylase gene (MTAP) since these two genes are tightly linked. Thus the cosmid of Kamb et al is an isolated polynucleotide comprising the sequence of SEQ ID no 1 which is a sequence region that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO 2. Necessarily then, the polynucleotide of Kamb et al. Comprises at least 21, 30, 40 or all contiguous bases from nucleotides 122-970 of SEQ ID NO 1 (limitations of claims 40-43). Since the polynucleotide of Kamb et al. Encodes the MTAP gene, it inherently meets the limitations of claims 45 and 46 that the encoded polypeptide promotes melanoma senescence and suppresses glioma cell tumor generation. The cosmid used in Kamb et al. was at least 849 base pairs in length since it contains the CDKN2 which is target than 849 base pairs (limitations of 47-

Art Unit: 1655

49). Kamb et al teaches a method for detecting a nucleic acid comprising a sequence encoding MTAP by hybridization with a probe comprising at least 21 bases of SEQ ID NO 1 because Kamb et al. teaches a Southern blot (Figure 2) was performed using human genomic DNA and a probe which was a cosmid which contains the MTAP gene. Therefore, a nucleic acid containing the MTAP would be detected by hybridization of the cosmid of Kamb et al since the same probe was used by Kamb et al. That was used in the claimed method (claims 78-83).

3. Claims 39-48,50-60, 67-76, 78-83, 88-94 are rejected under 35 U.S.C. 102(b) as being anticipated by Bolander et al. (1994)

Bolander et al. teach a chromosome fragments, vectors and host cells comprising the MTAP gene and methods of use identical to the claimed invention (see figure 4) because chromosome fragments that comprise the MTAP gene inherently comprises SEQ ID NO 1 encoding a polypeptide of SEQ ID NO 2.

4. Claims 95 and 96 are rejected under 35 U.S.C. 102(b) as being anticipated by Scaletti et al..Scaletti et al. Disclose methods of distinguishing tumor types by comparing chromosome 9p patterns between tumor types.

Art Unit: 1655

**NEW GROUNDS OF REJECTION**

5. Claims 39-42,45-50-66, 74-75,77-83, 88-94 are rejected under 35 U.S.C. 102(b) as being anticipated by, or in the alternative under 35 U.S.C. 103(a) as being obvious over Nobori et al.

Nobori et al. teach that methylthioadenosine phosphylase cDNA was isolated and used to probe a human lambda-phage cDNA library and a 2000 base pair fragment was found to contain the 3' end of the MTAP gene (page 753, col. 2, paragraph 3). This sequence was used as a probe for chromosome walking, I.e. in a hybridization detection reaction. The MTAP HindIII fragment was inserted into a vector and transformed into a host cell (page 754). It is noted that Nobori et al. Only discloses a 3' fragment of the human MTAP gene. However, the claims as written read on polynucleotides containing fragments of the MTAP gene as small as 10 bases.

However, the embodiments of the claims limited to a polynucleotide consisting of the MTAP gene would have been prima facie obvious over the teachings of Nobori et al. Because Nobori et al. disclose a highly specific probe for isolating the complete coding sequence for the MTAP gene by teaching a polynucleotide consisting of the 3' end of the MTAP gene. The ordinary artisan would have been highly motivated to obtain the remainder of the MTAP gene because Nobori et al. Taught that they has only isolated a portion of the coding sequence and any ordinary artisan would recognize the need to obtain the remainder of the gene sequence in order to be able the express the full length polypeptide. The ordinary artisan would have had a reasonable expectation for success because Nobori et al. Isolated a probe of 100% sequence

Art Unit: 1655

identity to the gene to be isolated such that very stringent hybridization conditions could be employed in the screening of the human cDNA of Nobori or genomic library to isolated clones containing the full length MTAP sequence. It would have been further obvious to have then expressed the full length MTAP polypeptide encoded by the MTAP nucleic acid obvious over Nobori et al. For the above reasons in order to have achieved the expected benefit of more easily and more quickly producing recombinant MTAP in larger quantities.

6. Claims 84-87 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nobori et al. or Bolander et al.

Nobori et al. teach that methylthioadenosine phosphylase cDNA was isolated and used to probe a human lambda-phage cDNA library and a 2000 base pair fragment was found to contain the 3' end of the MTAP gene (page 753, col. 2, paragraph 3). This sequence was used as a probe for chromosome walking, I.e. in a hybridization detection reaction. The MTAP HindIII fragment was inserted into a vector and transformed into a host cell page 754). It is noted that Nobori et al. Only discloses a 3' fragment of the human MTAP gene. However, the claims as written read on polynucleotides containing fragments of the MTAP gene as small as 10 bases.

Bolander et al. teach a chromosome fragments, vectors and host cells comprising the MTAP gene and methods of use identical to the claimed invention (see figure 4) because chromosome fragments that comprise the MTAP gene inherently comprises SEQ ID NO 1 encoding a polypeptide of SEQ ID NO 2.

Art Unit: 1655

Both Nobori et al. and Bolander et al. teach the association of the 9p21-22 region with cancers due to its frequent deletion in patients with various cancers and teach that this region was suspected to contain a number of tumor suppressor genes.


Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have packaged the polynucleotides and vectors taught by Nobori et al. Or Bolander et al. With detection reagents in a kit in order to achieve the expected benefit of providing probes to use in a method of screening for deletions of the 9p21-22 region as suggested by Nobori et al. And by Bolander et al. In a convenient form which was easier to distribute and market.

7. No claims are allowable over the prior art.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa Arthur whose telephone number is (703) 308-3988. The examiner can normally be reached on Monday-Thursday from 7:00AM to 1:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 3081152. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

  
LISA B. ARTHUR  
PRIMARY EXAMINER  
GROUP 1600-1600

November 22, 1999



## Interview Summary

Application No.  
08/674,311

Applicant(s)  
Olopade et al

Examiner  
Lisa Athur

Group Art Unit  
1655



All participants (applicant, applicant's representative, PTO personnel):

(1) Lisa Athur

(3) \_\_\_\_\_

(2) Pam Miner

(4) \_\_\_\_\_

Date of Interview Feb 8, 2000

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No. If yes, brief description:

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: None

Identification of prior art discussed:

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Attorney called to inform examiner that she did not receive a complete office action. Attorney stated that she received pages 1-5 only. Upon review of the application and the office action, examiner found that the copy of the office action in the case contained to copies of the past page of the office action, namely page 6. Examiner indicated that a supplemental office action containing the complete action would be mailed to application which would restart the period for response. Furthermore, attorney indicated that the address for amilling has changed to the following:

Mark Wilson, Fullbright and Kaworski, 600 Congress Ave, Suite 2400, Austin, TX 78701

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.